DJ PTA News: rapid can Therapeutics Corp.: rapid dose Therapeutics vaccine study COVID-19 and McMaster University receives a NSERC grant-for research and development
Corporate Communication for the Capital Market
Burlington (pta024 / 22.12.2021 / 14: 52)-Ontario-December 22, 2021- today, rapid can Therapeutics Corp. ("RDT" or the "Company") (CSE: can) and McMaster University ("McMaster") from the Natural Sciences and Engineering Research Council of Canada (NSERC) have received the last tranche of the Collaborative Research and Development grant of CAD 120,000 for the ongoing development of an orally administered vaccine candidate against COVID-19.
"we are pleased with the continued support of the Canadian government by NSERC to continue this important research," said Mark Upsdell, CEO of rapid can Therapeutics. "Global experts have called for a needle-free method to administer vaccines against COVID-19 and many other diseases, and our research activities are crucial to support the commercialisation of such innovation."
Dr. Alex Adronov, PhD, head of the McMaster University research team, adds: "this grant allows us to continue our efforts to develop oral thin-film therapeutics for a wide range of applications, including the inclusion of vaccine components for needle-free vaccinations."
Note: the Company neither expressly nor implicitly claims that its product has the ability to eliminate, cure or contain COVID-19.
About rapid can Therapeutics Corp. rapid can Therapeutics is a Canadian biotechnology company that revolutionizes drug administration through innovation. The company & APOs; s flagship product, QuickStripT, is a thin, orally soluble film that can be infused with an infinite list of active ingredients (nutraceutics, pharmaceuticals, vaccines, cannabis) that quickly enter the bloodstream, resulting in a rapid onset of action of the active substance.
Http: / / www.rapid-dose.com
For further information:
Contact for investors: mark Upsdell, CEO mupsdell @ rapid-dose.com + 1 (416) 477-1052
Media contact: Kim Robinson krobinson @ rapid-dose.com + 1 (905) 330-4055
Forward looking statements: certain information contained in this news release may contain forward-looking information within the meaning of applicable securities laws. All statements contained in this news release, other than historical facts, may be considered as forward-looking statements. Forward-looking statements are often characterized by terms such as & quot; can & quot;, & quot; should & quot;, & quot; expect & quot;, & quot; potentially & quot;, & quot; believe & quot;, & quot; intend & quot;, & quot; be & quot;, & quot; could & quot;, & quot; plan & quot;, & quot; expect & quot; or negate these terms and similar expressions. Statements containing forward-looking information, including, but not limited to, the delivery of devices and products using the QuickStripT product delivery method, the generation of recurring revenue, constitute, at the time of this press release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management with regard to future events or results, and are deemed appropriate on the basis of the information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks related to the general economic situation, adverse industry events, marketing costs, market losses, termination of WLM agreements, future legislative and regulatory developments related to cannabis, inability to raise sufficient capital from internal and external sources, and / or inability to raise sufficient capital on favourable terms, the cannabis industry in Canada in general, income tax and regulatory matters, the ability to implement its business strategies, competition, currency and interest rate fluctuations, and Readers are advised that the above list is not complete. It cannot be guaranteed that the statements of forward-looking information, even if deemed appropriate by RDT & APOs; s management at the time of their preparation, will prove to be accurate, as it cannot be guaranteed that the plans, intentions or expectations on which they are based will occur. Actual results and future events may differ materially from those expected in such forward-looking statements. Readers should not rely unreasonably on forward-looking statements. The forward-looking statements contained in this news release are expressly restricted by this warning.
(end)
Sender: rapid can Therapeutics Corp. address: 1121 walkers line, on L7N 2 Burlington country: Canada Contact: Kim Robinson Tel.: + 1 (905) 330-4055 e-mail: krobinson @ rapid-dose.com website: www.rapiddose.ca
ISIN (s): CA75339A1012 (share) stock exchanges:-other trading venues: CSE Canadian Securities exchange
[source: http: / / adhoc.pressetext.com / News / 164018113157]
©pressetext Nachrichtenagentur GmbH mandatory communications and financial news transmitted by pressetext.adhoc. Archive: http: / / adhoc.pressetext.com The sender is responsible for the content of the communication. Contact for inquiries: Adhoc @ pressetext.com or + 43-1-81140-300.
(end) Dow Jones newswires
December 22, 2021 08: 52 et (13: 52 GMT)
